Ffcm LLC increased its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 5.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 76,646 shares of the biopharmaceutical company’s stock after buying an additional 3,966 shares during the period. Ffcm LLC’s holdings in Bristol-Myers Squibb were worth $3,984,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Trust Co. of Virginia VA increased its holdings in Bristol-Myers Squibb by 105.7% during the fourth quarter. Trust Co. of Virginia VA now owns 50,048 shares of the biopharmaceutical company’s stock worth $2,601,000 after buying an additional 25,712 shares during the last quarter. Highwater Wealth Management LLC acquired a new position in Bristol-Myers Squibb during the fourth quarter worth $170,000. Yorktown Management & Research Co Inc increased its holdings in Bristol-Myers Squibb by 400.0% during the third quarter. Yorktown Management & Research Co Inc now owns 20,000 shares of the biopharmaceutical company’s stock worth $1,242,000 after buying an additional 16,000 shares during the last quarter. Hollencrest Capital Management increased its holdings in Bristol-Myers Squibb by 176.1% during the fourth quarter. Hollencrest Capital Management now owns 9,604 shares of the biopharmaceutical company’s stock worth $499,000 after buying an additional 6,126 shares during the last quarter. Finally, Northern Capital Management LLC acquired a new position in Bristol-Myers Squibb during the fourth quarter worth $3,907,000. Institutional investors and hedge funds own 73.35% of the company’s stock.
A number of equities analysts have commented on the stock. Zacks Investment Research cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Wednesday, January 16th. ValuEngine cut shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Friday, January 4th. William Blair reaffirmed an “outperform” rating on shares of Bristol-Myers Squibb in a research report on Tuesday, November 27th. Credit Suisse Group reaffirmed a “hold” rating and set a $59.00 price objective on shares of Bristol-Myers Squibb in a research report on Friday, February 15th. Finally, BMO Capital Markets reduced their price objective on shares of Bristol-Myers Squibb to $56.00 and set a “market perform” rating for the company in a research report on Tuesday, November 27th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $59.40.
Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, January 24th. The biopharmaceutical company reported $0.94 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.09. The company had revenue of $5.97 billion during the quarter, compared to analysts’ expectations of $5.95 billion. Bristol-Myers Squibb had a net margin of 21.95% and a return on equity of 48.99%. Bristol-Myers Squibb’s quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.68 earnings per share. As a group, analysts anticipate that Bristol-Myers Squibb Co will post 4.15 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be given a $0.41 dividend. The ex-dividend date is Thursday, April 4th. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.28%. Bristol-Myers Squibb’s payout ratio is presently 41.21%.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Further Reading: Bear Market – How and Why They Occur
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.